# Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension

Study · id `cardio:ct-nct05920005` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05920005](<https://clinicaltrials.gov/study/NCT05920005>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05920005

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 702 participants.

## Technical summary

Registry record NCT05920005. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-22 (actual); primary completion 2025-03-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 702 participants (enrolled count; ClinicalTrials.gov record NCT05920005, source copy `cardio:ctgov-nct05920005-2025-07-09`, retrieved 2026-10-26)
- Started: 2023-08-22 (actual) (ClinicalTrials.gov record NCT05920005, source copy `cardio:ctgov-nct05920005-2025-07-09`, retrieved 2026-10-26)
- Primary completion: 2025-03-31 (actual) (ClinicalTrials.gov record NCT05920005, source copy `cardio:ctgov-nct05920005-2025-07-09`, retrieved 2026-10-26)
- Completion: 2025-05-01 (actual) (ClinicalTrials.gov record NCT05920005, source copy `cardio:ctgov-nct05920005-2025-07-09`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT05920005, source copy `cardio:ctgov-nct05920005-2025-07-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05920005-2025-07-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension
- Acronym: OPTION TREAT
- Condition: Hypertension
- Intervention (Drug): candesartan cilexetil + chlorthalidone + amlodipine
- Intervention (Drug): Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
- Lead sponsor: Hospital Israelita Albert Einstein
- Lead sponsor class: OTHER
- Collaborator: Libbs Farmacêutica LTDA
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hospital Israelita Albert Einstein (`cardio:org-hospital-israelita-albert-einstein`)

## Provenance

Content hash: 64022ccb21f80e604520dbfcb6ae5e2d3247e66ae4bdd12a3eb6dfe9d0ca253c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
